A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib
Nihel Ammous‐Boukhris, Rania Abdelmaksoud‐Dammak, Ameni Feki, Souhir Khemiri, Slim Charfi, Tahia Sallemi‐Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad Gargouri · 2026
Read A Novel BRCA1 Pathogenic Variant in Tunisian Patient With High Grade Ovarian Cancer: Favorable Therapeutic Response to Olaparib by Nihel Ammous‐Boukhris, Rania Abdelmaksoud‐Dammak, Ameni Feki, Souhir Khemiri, Slim Charfi, Tahia Sallemi‐Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad Gargouri (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13542423.txt.
Description
Nihel Ammous-Boukhris and co-authors report a new gene fault in a Tunisian ovarian cancer case in a 2026 paper. The fault sits in BRCA1, a gene whose damage drives many such cancers. Faults there also open the door to a targeted drug family, the PARP inhibitors.
Their patient was a fifty-year-old woman with severe anemia from heavy bleeding. Scans showed no ovarian mass, but surgery found a belly lining nodule. Gene tests on tumor and blood found a ten-letter deletion in BRCA1, seen only in the tumor. Databases class the new fault as disease-causing. After standard chemotherapy, the drug olaparib kept her disease-free for twenty-three months with good tolerance.
Catalog record
| CREATOR | Nihel Ammous‐Boukhris, Rania Abdelmaksoud‐Dammak, Ameni Feki, Souhir Khemiri, Slim Charfi, Tahia Sallemi‐Boudawara, Jamel Daoud, Afef Khanfir, Raja Mokdad Gargouri |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 18 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |